Bemarituzumab (bema), a first-in-class humanized IgG1 monoclonal antibody, selectively binds to the 2b isoform of the fibroblast growth factor receptor (FGFR2b). Bemarituzumab (FPA144) is a first-in-class humanized immunoglobulin G1 monoclonal antibody specific to the splice-variant FGFR2b that inhibits binding of the ligands FGF7, FGF10, and FGF22. Specifically, bemarituzumab does not inhibit binding of FGF23, the ligand responsible for phosphate and vitamin D metabolism, thereby potentially avoiding the risk of hyperphosphatemia associated with pan-FGFR tyrosine kinase inhibitors. Bemarituzumab is also glycoengineered for increased affinity for the human Fc gamma RIII receptor expressed on natural killer cells, enabling enhanced antibody-dependent cell-mediated cytotoxicity.
Research Grade Bemarituzumab
Overview
Catalog No.
HB863016
Host species
Humanized
Species reactivity
Human
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Purity
>95% purity as determined by SDS-PAGE.
Clonality
Monoclonal
Isotype
IgG1-kappa
Applications
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Target
K-sam, KSAM, CD332, Keratinocyte growth factor receptor, Fibroblast growth factor receptor 2, FGFR-2, FGFR2, KGFR, BEK
Purification
Protein A/G purified from cell culture supernatant.
Endotoxin level
Please contact the lab for this information.
Expression system
Mammalian Cells
Accession
P21802
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternative name
FPA144, FPA-144, FPA114-A, 1952272-74-0
Note
For research use only. Not suitable for clinical or therapeutic use.
Description
Images
Bioactivity
SEC-HPLC detection for Research Grade Bemarituzumab.
SDS-PAGE
SDS-PAGE for Research Grade Bemarituzumab.